<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930136</url>
  </required_header>
  <id_info>
    <org_study_id>CRESO 2</org_study_id>
    <nct_id>NCT01930136</nct_id>
  </id_info>
  <brief_title>Effects of Caloric Restriction in Obesity and Type 2 Diabetes</brief_title>
  <acronym>CRESO2</acronym>
  <official_title>Long-term Effects of Caloric Restriction on Metabolic, Renal End Retinal Health in Subjectsaffected by Obesityand Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Superiore di Sanit√†</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates whether a long-term 25% caloric restriction can prevent onset and/or&#xD;
      progression of renal function deterioration, retinal involvement and cardiovascular&#xD;
      complications in overweight/obese type 2 diabetic patients, trough the amelioration of&#xD;
      concomitant metabolic abnormalities such as visceral obesity, insulin resistance,&#xD;
      dyslipidemia, hypertension and inflammation.&#xD;
&#xD;
      The main aim of the study is therefore to evaluate the role of calorie restriction (CR) on&#xD;
      subjects at risk of nephropathy. Secondary aims are to better understand the relationship&#xD;
      between CR and the following aspects: renal disease and its associated metabolic&#xD;
      abnormalities, retinopathy and cardiovascular complications, quality of life and treatment&#xD;
      cost.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end</measure>
    <time_frame>At baseline, 6, 12 and 24 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Calorie restriction (25%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ad libitum health diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Calorie restriction (25%)</intervention_name>
    <arm_group_label>Calorie restriction (25%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Ad libitum health diet</intervention_name>
    <arm_group_label>Ad libitum health diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age &gt;40 years;&#xD;
&#xD;
          -  Type 2 diabetes (ADA criteria);&#xD;
&#xD;
          -  UAE &lt;300 mg/24h;&#xD;
&#xD;
          -  Body mass index (BMI)&gt;27kg/m2;&#xD;
&#xD;
          -  Serum creatinine &lt; 1.2 mg/dL;&#xD;
&#xD;
          -  No major changes in calorie, protein and sodium intake in the last 6 mos;&#xD;
&#xD;
          -  No major changes in concomitant treatments with blood pressure, glucose or lipid&#xD;
             lowering agents since 6 and 3 months respectively;&#xD;
&#xD;
          -  Patients legally able to give written informed consent to the trial (signed and dated&#xD;
             by the patient);&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Concomitant non-diabetic renal disease or ischemic kidney disease;&#xD;
&#xD;
          -  Primary or immune-mediated renal disease;&#xD;
&#xD;
          -  Urinary tract obstruction or infection;&#xD;
&#xD;
          -  Treatment with steroids and/or non-steroid anti-inflammatory agents;&#xD;
&#xD;
          -  Treatment with thiazide or loop diuretics that, on the basis of the Investigator's&#xD;
             judgment, might sustain hypovolemia and/or sodium depletion (with secondary kidney&#xD;
             hypoperfusion/hypofiltration);&#xD;
&#xD;
          -  Hearth failure and/or hemodynamically significant left ventricular systolic&#xD;
             dysfunction, cirrhosis, uncontrolled hyperglycemia resulting in glycosuria,&#xD;
             hyper/hyponatremia of any cause;&#xD;
&#xD;
          -  Previous surgical procedures for weight loss;&#xD;
&#xD;
          -  Previous episodes of depression, or suicide attempts;&#xD;
&#xD;
          -  Chronic abuse of alcohol and drugs;&#xD;
&#xD;
          -  Pregnancy, ineffective contraception or peri-menopausal age;&#xD;
&#xD;
          -  Cancer or any chronic disease that might affect the completion of the study;&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease (COPD) in treatment with positive airway&#xD;
             pressure;&#xD;
&#xD;
          -  Unwillingness or inability to adhere to CR intervention over the entire 24-months&#xD;
             intervention period;&#xD;
&#xD;
          -  Legal incapacity and/or other circumstances rendering the patient unable to understand&#xD;
             the nature, scope and possible consequence of the trial;&#xD;
&#xD;
          -  Evidence of an uncooperative attitude;&#xD;
&#xD;
          -  Any evidence that patient will not be able to complete the trial follow-up;&#xD;
&#xD;
          -  Inability to fully understand the potential risks and benefits of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Center for Rare Diseases</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calorie restriction</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetic nephropathy prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

